News | April 30, 2026
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
The agreement could rise to $900 million if key commercial milestones are met
The agreement could rise to $900 million if key commercial milestones are met
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
Stakeholders call for coordinated action on diagnostics, vaccines, and health system readiness as the monsoon season approaches
The unit is equipped with advanced monitoring systems and supported by a multidisciplinary team
The long-term exposure to fine particulate matter (PM2.5) increases overall cancer risk by 11%
ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose
Subscribe To Our Newsletter & Stay Updated
